About Pyruvate dehydrogenase E1 component subunit beta, mitochondrial
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) is a protein
from Homo sapiens identified by UniProt accession
P11177, 359 residues long.
MolForge cross-references it against 0 known binders and
163 disease associations.
Target properties
| Protein name | Pyruvate dehydrogenase E1 component subunit beta, mitochondrial |
| UniProt accession | P11177 |
| Gene | PDHB |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (163)
Diseases linked to this target (Open Targets).
- pyruvate dehydrogenase E1-beta deficiency · score 0.78
- neurodegenerative disease · score 0.39
- Leigh syndrome · score 0.19
- total blood protein measurement · score 0.19
- pyruvate dehydrogenase deficiency · score 0.19
- genetic disorder · score 0.18
- low density lipoprotein cholesterol measurement · score 0.16
- breast carcinoma · score 0.16
- hematocrit · score 0.15
- cortical thickness · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11177-F1 | alphafold | PREDICTED | 94.32 | — |
Amino-acid sequence (359 residues)
MAAVSGLVRR PLREVSGLLK RRFHWTAPAA LQVTVRDAIN QGMDEELERD EKVFLLGEEV AQYDGAYKVS RGLWKKYGDK RIIDTPISEM GFAGIAVGAA MAGLRPICEF MTFNFSMQAI DQVINSAAKT YYMSGGLQPV PIVFRGPNGA SAGVAAQHSQ CFAAWYGHCP GLKVVSPWNS EDAKGLIKSA IRDNNPVVVL ENELMYGVPF EFPPEAQSKD FLIPIGKAKI ERQGTHITVV SHSRPVGHCL EAAAVLSKEG VECEVINMRT IRPMDMETIE ASVMKTNHLV TVEGGWPQFG VGAEICARIM EGPAFNFLDA PAVRVTGADV PMPYAKILED NSIPQVKDII FAIKKTLNI
Explore Pyruvate dehydrogenase E1 component subunit beta, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets